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Abstract
Background: KRAS mutational analysis is the standard of care prior to initiation of treatments targeting the
epidermal growth factor receptor (EGFR) in patients with metastatic colorectal cancer. Sensitive methods are
required to reliably detect KRAS mutations in tumor samples due to admixture with non-mutated cells. Many
laboratories have implemented sensitive tests for KRAS mutations, but the methods often require expensive
instrumentation and reagents, parallel reactions, multiple steps, or opening PCR tubes.
Methods: We developed a highly sensitive, single-reaction, closed-tube strategy to detect all clinically significant
mutations in KRAS codons 12 and 13 using the Roche LightCycler® instrument. The assay detects mutations via
PCR-melting curve analysis with a Cy5.5-labeled sensor probe that straddles codons 12 and 13. Incorporating a fast
COLD-PCR cycling program with a critical denaturation temperature (Tc) of 81°C increased the sensitivity of the
assay >10-fold for the majority of KRAS mutations.
Results: We compared the COLD-PCR enhanced melting curve method to melting curve analysis without COLD-
PCR and to traditional Sanger sequencing. In a cohort of 61 formalin-fixed paraffin-embedded colorectal cancer
specimens, 29/61 were classified as mutant and 28/61 as wild type across all methods. Importantly, 4/61 (6%) were
re-classified from wild type to mutant by the more sensitive COLD-PCR melting curve method. These 4 samples
were confirmed to harbor clinically-significant KRAS mutations by COLD-PCR DNA sequencing. Five independent
mixing studies using mutation-discordant pairs of cell lines and patient specimens demonstrated that the COLD-
PCR enhanced melting curve assay could consistently detect down to 1% mutant DNA in a wild type background.
Conclusions: We have developed and validated an inexpensive, rapid, and highly sensitive clinical assay for KRAS
mutations that is the first report of COLD-PCR combined with probe-based melting curve analysis. This assay
significantly improved diagnostic accuracy compared to traditional PCR and direct sequencing.
Background
KRAS (Kirsten rat sarcoma virus homolog 2) is a mem-
brane-anchored G-protein that acts downstream of the
epidermal growth factor receptor (EGFR) to activate
pro-growth and anti-apoptotic pathways, including the
MAP kinase and PI3 kinase pathways [1]. Mutations in
codons 12 and 13 of the KRAS gene confer resistance to
drugs targeted at EGFR by impairing GTPase activity,
which results in constitutive EGFR-independent signal-
ing. KRAS is one of the most frequently mutated
oncogenes in human cancer, with significant mutation
rates in common epithelial malignancies such as colon
cancer (~40%), lung cancer (~20%), gastric cancer
(~10%), and pancreatic cancer (~65%) (COSMIC data-
base; http://www.sanger.ac.uk/genetics/CGP/cosmic/)
[2,3].
T h er o l eo fKRAS mutation status in clinical decision
making is best defined for colon cancer. Several large
randomized-controlled trials demonstrated no benefit
from expensive anti-EGFR drugs such as cetuximab
(Erbitux™) in patients with KRAS-mutant colon cancer
[4,5]. The National Comprehensive Cancer Network
(NCCN) now recommends KRAS testing prior to initia-
tion of anti-EGFR therapy in colon cancer patients [6].
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testing to guide therapy in patients with non-small cell
lung cancer [7,8].
Greater than 95% of KRAS mutations occur in codon
12 or codon 13. Within these codons G12 D (GGT to
GAT), G12V (GGT to GTT), and G13 D (GGC to
GAC) comprise ~80% of the mutations [2,4]. Less fre-
quent mutations include G12 S (GGT to AGT), G12C
(GGT to TGT), G12R (GGT to CGT), and G12A (GGT
to GCT). Silent mutations are exceedingly rare http://
www.sanger.ac.uk/genetics/CGP/cosmic/.
CO-amplification at Lower Denaturation temperature
(COLD)-PCR is a recently described method to selec-
tively amplify mutant alleles in a wild type background
that does not require any additional instrumentation or
reagents to implement [9]. Two forms of COLD-PCR
are described: fast COLD-PCR and full COLD-PCR
(reviewed in [10]). Fast COLD-PCR enriches G:C to A:T
mutations that slightly, but predictably lower the melt-
ing temperature (Tm) of the PCR amplicon, by using a
critical denaturation temperature (Tc)t h a tf a v o r sP C R
amplification of the mutant allele. Full COLD-PCR theo-
retically enhances detection of any type of mutation via
conditions which promote annealing of WT:mutant
pairs and selective denaturation of these heteroduplexes
at an empirically determined Tc. As the name implies,
fast COLD-PCR has the advantage of being more rapid
than full COLD-PCR (1-2 hours of instrument time
compared to 5-8 hours) and is also easier to trouble-
shoot and implement in our experience. Fast COLD-
PCR is ideal for KRAS codon 12 and 13 mutational ana-
lysis because >90% of the mutations are G:C to A:T
c h a n g e s( G 1 2D ,G 1 2 V ,G 1 2S ,G 1 2 C ,G 1 3 D ) ,a n dt h e
remaining common mutations are Tm -neutral G:C to
G:C changes (G12R and G12A).
Here, we report a novel strategy for mutation detec-
tion that combines fast COLD-PCR with two-probe
melting curve analysis using the LightCycler® instru-
ment. By incorporating COLD-PCR we achieve >10-fold
enhancement for the majority of KRAS mutations with a
sensitivity of ~1% mutant allele in a wild type
background.
Methods
Patient tumor samples and DNA extraction
All clinical specimens consisted of DNA prepared from
formalin-fixed paraffin-embedded (FFPE) tissue from
patients with sporadic colorectal carcinoma. De-identi-
fied residual clinical specimens were obtained in accor-
dance with the declaration of Helsinki and ethics
guidelines of the local institutional review board. We
obtained a total of 61 de-identified specimens: 10 DNA
specimens from the University of Texas MD Anderson
Cancer Center, 4 specimens of unstained FFPE tissue
sections with corresponding hematoxylin-eosin (HE)
stained slides from the University of Chicago, and 47
DNA specimens prepared from FFPE tissue from color-
ectal cancer specimens at the University of Washington.
HE-stained slides were used as a guide to manually dis-
sect areas of tumor tissue from unstained slide sections.
Genomic DNA was prepared with the Gentra Puregene
DNA Isolation Kit (Qiagen, Cat. No. 158489).
KRAS mutational detection by Regular- and COLD-PCR
enhanced melting curve analysis
Our basic melting-curve strategy to identify KRAS muta-
tions is a modification of a procedure described by Niki-
forova and colleagues [11]. The assay is a PCR
fluorescence resonance energy transfer (FRET) hybridi-
zation probe assay performed with a LightCycler® carou-
sel instrument (Roche Molecular Biochemicals,
Manheim Germany). This format requires a pair of pri-
mers and two fluorescently labeled oligonucleotide
probes and relies on FRET between two probes that
hybridize adjacent to one another (Figure 1). For the
detection of KRAS codon 12/13 mutations, the Cy5.5-
labeled probe spans this region, and the products are
distinguished based on their distinct Tm, which reflects
the thermodynamic stability of the perfectly comple-
mentary and mismatched probe-target duplexes. The
wild-type Tm is 69.5 ± 0.5°C, and the mutant Tm is 62.8
± 1°C. The assay cannot reliably determine the exact
base change based on the Tm. The primers and probes
are given in Table 1. Each 20 μl PCR reaction contained
2 μl 10× LightCycler® FastStart DNAHyb Master mix
(Roche Cat No. 03 002248 001), 0.5 units of LightCy-
cler® uracil N-glycosylase enzyme (UNG) (Roche Cat
No. 03539806001), 2 mM final MgCl2 concentration, 30
pmol KRAS-F (1.5 μM final concentration), 10 pmol
KRAS-R (0.5 μM final concentration), 4 pmol anchor
probe (0.2 μM final concentration), and 4 pmol sensor
probe (0.2 μM final concentration). Template DNA was
added at 10-200 ng per reaction. PCR reactions were set
up in glass LightCycler® Capillaries (Roche Cat. No. 1
Sensor
Codon
12/13
KRAS-F
KRAS-R Anchor
164 bp amplicon
Exon 2 Intron 2
Figure 1 Melting Curve Assay Design. PCR primers are designed
within introns of the functional KRAS (Ki-Ras2) gene on
chromosome 12 to avoid amplification of a KRAS (Ki-Ras1)
pseudogene on chromosome 6. A Cy5.5-labeled wild type sensor
probe sits over the mutation hotspot at codons 12 and 13. When a
KRAS mutation is present, the sensor probe melts off at a lower Tm.
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cler® 2.0 carousel instruments. For the regular PCR
melting curve assay (not COLD-PCR enhanced) the
cycling program steps were as follows: 1) UNG step to
remove carry-over amplicon, 40°C for 10 min, 2) activa-
tion of antibody-inhibited Taq polymerase, 94°C for 10
min, 3) cycling 94°C 1 s, 52°C 20 s, 72°C 10 s for 45
total cycles, 4) melting curve with continuous tempera-
ture ramping at 0.15°C/s from 45°C to 80°C, and 5)
Cooling to 40°C. The COLD-PCR enhanced cycling pro-
gram is shown in Table 2. An initial 10 cycles of regular
PCR are performed to build up product, followed by 40
cycles of COLD-PCR with a critical denaturation tem-
perature (Tc) of 81°C which favors amplification of
mutant alleles. We determined the Tc empirically by
progressively lowering the denaturation temperature
from 84°C ® 82°C ® 81°C ® 80°C ® 79°C. Melting
curves were produced in both mutant and wild type
samples down to Tc =8 0 ° C .W ec h o s et h eTc at 81°C
because the melting curves were difficult to interpret at
Tc = 80°C due to reduced PCR efficiency and increased
signal-to-noise ratio (Additional file 1 Figure S1).
Regular- and COLD-PCR enhanced Sanger DNA
sequencing
We used KRAS-F and KRAS-R primers (Table 1) for
both PCR amplification and DNA sequencing. For DNA
sequencing, regular- or COLD-PCR reactions were per-
formed as described above except that the anchor and
sensor probes were not added to the reactions and ther-
mocycling was performed on a Bio-Rad C1000 instru-
ment. PCR products were purified using DNA Clean &
Concentrator™-5 (Zymo Research) and eluted in a 30 μl
volume of elution buffer (Cat No D4003, D4004, D4013
& D4014). Each 10 μl sequencing reaction included 2 μl
Big Dye Terminator v3.1 (Applied Biosystems, ABI) 2 μl
5× sequencing buffer (ABI), 4 pmol of sequencing pri-
mer (either KRAS-F or KRAS-R), and 200-300 ng puri-
fied PCR product. Sequencing reactions were cleaned up
using AutoSeq G-50 Sephadex columns (Amersham
Table 1 Primer and Probe Sequences (adapted from [11])
Primer/
Probe
Sequence Position Chr. 12
KRAS-F 5’-AAG GCC TGC TGA AAA TGA CTG-3’ Intron 1/Exon 2 boundary 25398312-
25398332
KRAS-R 5’-GGT CCT GCA CCA GTA ATA TGC A-3’ Intron 2 25398168-
25398189
Anchor
Probe
5’-CGT CCA CAA AAT GAT TCT GAA TTA GCT GTA TCG TCA AGG CAC T-
fluorescein-3’
Exon 2 25398228-
25398270
Sensor Probe 5’-Cy5.5-TGC CTA CGC CAC CAG CTC CAA-phosphate-3’ Exon 2 spanning codons 12/
13
25398273-
25398293
Chr.12: genomic numbering on chromosome 12, human genome build 19 (hg19, February 2009 build).
Table 2 Fast COLD-PCR Cycling Program
Step Temp Time Analysis Mode Acquisition Mode
UNG 40°C 10 m None None
Denaturation 94°C 10 m None None
Regular-PCR (10 cycles) 94°C 1 s None None
52°C 20 s None None
72°C 10 s None None
COLD-PCR (40 cycles) 81 °C (Tc) 1 s None None
Ramp 2.0°C/s 52°C 20 s Quant Single
72°C 10 s None None
Melting curve 94°C 5 s None None
45°C 30 s None None
80°C Ramp 0.15°C/s Melting Continuous
Cooling 40°C 10 s None None
UNG: Uracil-N-Glycosylase; Temp: Temperature.
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instrument, and analyzed with Mutation Surveyor soft-
ware (Softgenetics).
We sequenced a total of 30 out of 61 samples includ-
ing all 4 discrepant samples that were re-classified as
KRAS-mutant by the COLD-PCR melting curve analysis
(Additional file 2 Table S1). Two of the four discrepant
samples had very low mutant peaks by COLD-PCR
sequencing using the same thermocycling conditions
(Tc= 81°C, Table 2) that produced easily discernable
mutant peaks in the COLD-PCR melting curve assay,
presumably because the melting curve analysis is inher-
ently more sensitive than sequencing. For this reason,
we lowered the Tc to 79.4°C to further enhance amplifi-
cation of minority mutant alleles and confirm the KRAS
mutations we detected in the 4 discrepant samples. We
selected the Tc of 79.4°C after we tried Tc ranging from
79-81°C at 0.2°C increments and determined that the Tc
of 79.4°C was the lowest denaturation temperature in
which PCR product from a wild type sample was still
visible an agarose gel. We repeated COLD-PCR sequen-
cing with Tc = 79.4°C a total of 3 times for each of the
4 discrepant samples, obtaining concordant KRAS-
mutant results and appropriately negative KRAS-wild
type controls on each run.
Confirmation of Discrepant Specimens With An
Alternative Assay
In addition to COLD-PCR sequencing, we confirmed
the 4 discrepant specimens using the Lightmix KRAS
mutation detection kit following the manufacturer’s
instructions (TIB Molbiol, Cat#04-0416-08). This assay
uses a locked nucleic acid oligomer competitor and has
a stated sensitivity of at least 1% for mutant allele in a
wild type background (Additional file 1 Figure S2).
Mixing/Sensitivity Studies
We performed two types of mixing studies to estimate
sensitivity: (1) KRAS-mutant colorectal cancer cell lines
mixed with KRAS-WT peripheral blood leukocyte DNA,
and (2) KRAS-mutant FFPE DNA mixed with KRAS-
WT FFPE DNA. We used a total of three KRAS-mutant
colorectal cancer cell lines, SW480 (homozygous G12V;
GGT to GTT), HCT116 (heterozygous G13D; GGC to
GAC) and LS174T (heterozygous G12D; GGT to GAT),
and two KRAS-mutant FFPE colorectal cancer samples
(one G12 D and one G13D). The undiluted G12 D and
G13 D FFPE samples both had ~ 25% KRAS mutant
allele based on a visual estimate of tumor nuclear con-
tent and on the mutant:WT peak height ratios in regu-
lar PCR melting curve analysis (data not shown). To
control for potential differences in ploidy between sam-
ples and variation in DNA preparations that may con-
found the interpretation of mixing studies, we first
adjusted each DNA preparation so that the cycle thresh-
olds (Ct) of all mutant and WT samples were within 0.5
of each other (PCR-efficiency matched). Mutant cell
lines or FFPE DNA samples were mixed in the following
ratios (mutant%/WT%): 50/50, 20/80, 10/90, 5/95, 2/98,
1/99. We performed mixing studies in duplicate on a
total of 5 unique mutant:WT pairs.
As an alternative measure of sensitivity, we tested 20%
(G13C) and 1% (G12C) KRAS-mutant control DNA pro-
vided with the Lightmix KRAS mutation detection kit
(TIB Molbiol, cat # 04-0416-08, Lot#4160902).
Results
Establishing and Validating COLD-PCR Conditions
To establish the critical denaturation temperature (Tc)
for COLD-PCR melting curve analysis we selected a
G12C KRAS-mutant FFPE colorectal cancer specimen
with ~10% mutant allele based on a visual estimate of
tumor nuclei and the mutant/WT melting peak height
ratio using regular PCR. The mutant/WT peak height
ratio increased by an average of 6.3-fold in this “low-posi-
tive” patient sample as the Tc was lowered from 84°C ®
82°C ® 81°C (Figure 2). COLD-PCR DNA sequencing
confirmed a proportional increase in the mutant T base
at the first position of codon 12 (G12C = GGT®TGT) as
the Tc was lowered (Figure 2 insets). We found that using
a Tc lower than 81°C further enhanced the relative pro-
portion of mutant allele, but reduced PCR efficiency to a
degree that made it more difficult to interpret melting
peaks (Additional file 1 Figure S1).
We next validated the COLD-PCR melting curve assay
using FFPE colorectal cancer specimens with distinct
characterized KRAS mutations. COLD-PCR enhanced
detection of G:C to A:T mutations (G12 D, G13 D,
G12C, G12V) between 9.8 and 14.0 fold compared to
regular PCR (Summarized in Table 3). Importantly, the
COLD-PCR reaction conditions we established did not
diminish detection of Tm -neutral G:C to G:C mutations
(G12R and G13R). Surprisingly, the fast COLD-PCR
reaction conditions actually enhanced the detection of a
G13R (GGC to CGC) mutation, which we did not expect
to enhance based on a Tm -neutral G > C change. We
hypothesize that this enrichment is due to local sequence
effects or to a small amount of WT:mutant heteroduplex
formation during the primer annealing step, which favors
amplification of mutant alleles by the same mechanism
as full COLD-PCR (see Background for discussion of fast
vs. full COLD-PCR) [10].
Sensitivity of the COLD-PCR Enhanced Melting Curve
Assay
To determine the sensitivity of the COLD-PCR melting
curve assay to detect low quantities of mutant allele in
WT background we adopted two complementary
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with KRAS-WT peripheral blood leukocyte DNA, and
(2) KRAS-mutant FFPE tumor DNA with KRAS-WT
FFPE tumor DNA at mutant:WT ratios of 50/50, 20/80,
10/90, 5/95, 2/98, and 1/99. Prior to mixing we ensured
the PCR-efficiency of each sample in a pair was matched
within 0.5 Ct because variations in DNA quality, ploidy,
and sample preparation may favor the amplification of
one sample over the other and confound the estimation
of sensitivity [12]. In a total of 5 unique sample pairings
which included G12 D, G13 D, and G12V-mutant DNA,
the assay could readily detect KRAS mutations down to
1% mutant allele in each case with COLD-PCR enhance-
ment, but only down to 10% mutant allele with regular
PCR (Figure 3).
As a second measure of sensitivity, we ran commercial
20% (G13C) and 1% (G12C) KRAS-mutant control DNA
(TIB Molbiol, Lot No. 4160902). The COLD-PCR
enhanced melting curve assay correctly classified both
controls as KRAS-mutant with a mutant:WT peak
height ratio of 3.5 for the 20% G13C control, and 0.3
for the 1% G12C control (Additional file 1 Figure S3).
We next assessed if the COLD-PCR enhanced melting
curve assay was sensitive enough to eliminate the need
f o rt u m o rd i s s e c t i o ni naKRAS-mutant sample with a
low percentage (~3%) of tumor cells. We confirmed that
both regular-PCR melting curve analysis and Sanger
sequencing detected a KRAS mutation (G12D) when
DNA was prepared with morphology-guided dissection
to enrich for tumor cells in our standard fashion. We
then tested a DNA sample prepared from the same
tumor specimen without dissection (scraping the whole
slide). The COLD-PCR enhanced melting curve assay
readily detected the KRAS mutation when the whole
slide was scraped, whereas the result with regular PCR
melting curve analysis was equivocal (Figure 4).
COLD-PCR Enhanced Melting Curve Analysis Detects
Mutations That Are Missed By Regular PCR and Direct
Sanger Sequencing
W ec o m p a r e dt h eC O L D - P C Rm e l t i n gc u r v ea s s a yt o
regular PCR melting analysis in a cohort of 61 FFPE col-
orectal cancer specimens which included 14 blinded
samples that had KRAS testing done previously at out-
side institutions. KRAS mutations were detected in
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Figure 2 Optimization of COLD-PCR Conditions.AG 1 2 C( GGT-
TGT) KRAS-mutant colorectal cancer sample with approximately 10%
mutant allele was tested at progressively lower critical denaturation
temperatures (Tc). As the Tc was progressively lowered, the height of
the mutant melting peak at 62.5°C increased relative to the height
of the wild-type melting peak at 70°C. DNA sequencing performed
on COLD-PCR products corroborated an increase in the peak height
of the mutant T base (c.34 G > T) at the first position of codon 12
(compare top and bottom panel insets).
Table 3 COLD-PCR Enhancement According to Specific KRAS Mutation
Mutation Base Change Frequency in Colorectal Cancer Predicted To Enhance With Fast COLD-PCR? Fold-Enhancement With COLD-PCR
G12D GGT to GAT 35% Yes 11.5
G12V GGT to GTT 22% Yes 11.5
G13D GGC to GAC 19% Yes 9.8
G12C GGT to TGT 9% Yes 14.0
G12S GGT to AGT 7% Yes ND
G12A GGT to GCT 7% No ND
G12R GGT to CGT 1% No 1.1
G13R GGC to CGC < 1% No 2.5
Other Multiple < 1% Yes/No ND
ND = no data; Frequency Is Based on KRAS Mutations Colorectal Cancer Reported in the COSMIC Database accessed July 2010 http://www.sanger.ac.uk/perl/
genetics/CGP.
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melting curve analysis and, importantly, in an addi-
tional 4 samples (33/61 total; 54%) by COLD-PCR
enhanced melting curve analysis only (Table 4; Addi-
tional file 2 Table S1). Regular Sanger sequencing did
not detect mutations in the 4 samples that were re-
classified from KRAS-WT to KRAS-mutant by COLD-
PCR, presumably because the mutant allele % was
below the limit of detection (sensitivity ~20 percent
for standard sequencing). However, COLD-PCR
enhanced DNA sequencing confirmed that the 4 re-
classified samples each harbored a clinically significant
KRAS mutation (Additional file 3; Figure 5; see meth-
ods section for a detailed discussion of COLD-PCR
sequencing). KRAS mutations in the 4 re-classified
samples were also confirmed using the TIB Molbiol
Lightmix assay, which has a stated sensitivity of at
least 1% (Additional file 1 Figure S2). Sequencing of an
additional 26 specimens that were concordant by regu-
lar- and COLD-PCR confirmed the KRAS melting
curve analysis result in all cases (Additional file 2
Table S1).
Among the 14 specimens from outside institutions,
KRAS results were concordant using the less sensitive
regular PCR melting curve analysis and Sanger sequen-
cing (7/14 KRAS-mutant; 7/14 KRAS-WT). However, we
re-classified 1/14 of these specimens as KRAS-mutant by
both COLD-PCR melting curve analysis and COLD-PCR
sequencing. The method used by the outside laboratory
to identify KRAS mutations was regular sequencing,
which explains why the KRAS mutation in that speci-
men was not originally detected.
Discussion
Cancer tissue presents challenges for KRAS mutation
analysis because each specimen is a unique mixture of
tumor and non-tumor cells. A typical formalin-fixed
paraffin-embedded colorectal cancer specimen might
have between 2-50% tumor cells, which corresponds to
1-25% mutant allele when the tumor is diploid and a
heterozygous mutation is present. To enrich the propor-
tion of tumor cells most laboratories (including ours)
manually dissect areas of tumor tissue from unstained
sections guided by an HE-stained slide. This approach
improves mutation detection, but tumors with a diffuse
growth pattern or dense inflammatory infiltrate may still
have a significant proportion of “contaminating” non-
tumor DNA after tumor dissection. For this reason,
m e t h o d ss u c ha sC O L D - P C Ra nd peptide nucleic acid
(PNA) clamping have been developed to increase the
sensitivity of mutation analysis by selectively amplifying
mutant alleles in a wild type background [9,10,13].
Here, we demonstrate that COLD-PCR combined with
probe-based melting curve analysis can reproducibly
detect down to 1% KRAS-mutant allele in a wild type
background. This is comparable to the sensitivity
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Figure 3 Sensitivity of the Assay. Five independent mixing studies were performed in duplicate using KRAS-mutant cell lines (SW480, LS174T,
HCT116) paired with wild-type peripheral blood leukocyte DNA and KRAS-mutant formalin-fixed paraffin-embedded (FFPE) tissue samples paired
with KRAS-WT FFPE samples as described in the methods section. For each mixing study the mutant melting peak height was measured as a
percentage of the maximum mutant peak height observed in the undiluted KRAS-mutant sample specific to the particular Mutant:WT pairing.
The left panel shows the average and SD (error bars) of the %mutant peak height across the 5 mixing studies using regular- (gray triangles) or
COLD-PCR (black squares) conditions. Mutant peak heights were consistently above the limit of detection down to 1% mutant allele using
COLD-PCR compared to 10% mutant allele with regular PCR. The right panel shows an example of one of the mixing studies (SW480 cell line;
homozygous G12V) used to generate the sensitivity graph in the left panel. Mutant melting peaks are not clearly discernible for 1%, 2%, and 5%
KRAS-mutant samples using regular PCR (top right panel), but are readily detected using COLD-PCR (bottom right panel).
Pritchard et al. BMC Clinical Pathology 2010, 10:6
http://www.biomedcentral.com/1472-6890/10/6
Page 6 of 10reported with PNA clamping methods applied to melt-
ing curve analysis [14,15]. We show that our COLD-
PCR method can readily detect the 20% and 1% KRAS-
mutant controls used in the nucleic acid clamping-based
TIB Molbiol commercial kit for the LightCycler®
instrument, with substantially less expensive reagents (~$5
compared to ~$100 per reaction). Limitations of our study
include the relatively small sample size (n = 61), and lack
of validation of the full range of rare KRAS mutations. A
larger scale study is required to determine the assay’s per-
formance on the full complement of rare KRAS mutations.
A recent editorial on COLD-PCR technology sug-
gested that “The utility of COLD-PCR will be greatly
enhanced if this approach can be demonstrated to com-
pletely eliminate microdissection steps or at least to sub-
stantially reduce the tumor percentage required....[16].”
We show that the COLD-PCR melting curve assay is
sensitive enough to readily detect a KRAS mutation
without tumor dissection in a sample with only ~3%
tumor cells. Despite this, we believe it is prudent to con-
tinue dissection for tumor enrichment because addi-
tional mutational testing may be required on the same
Regular PCR
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Figure 4 KRAS Mutation Detection Without Dissection. DNA was prepared from a G12 D KRAS-mutant colorectal cancer resection specimen
with ~3% tumor cells by scraping the tissue from the entire slide without tumor dissection. The KRAS result was equivocal using regular-PCR
(upper left panel), but a mutation was clearly detected using COLD-PCR (lower left panel). The corresponding HE-stained slide and region of
tumor are depicted in the right panel.
Table 4 Comparison of Regular- and COLD-PCR in 61
FFPE Samples
COLD-PCR
Pos Lo-Pos WT Total
Regular PCR Pos 19 0 0 19
Lo-Pos 10 0 0 10
WT 4 0 28 32
Total: 33 0 28 61
FFPE: Formalin-fixed paraffin-embedded Pos: Positive for KRAS mutation;
Lo-Pos: Positive for KRAS mutation near the limit of detection; WT: Wild Type
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lower sensitivity.
Among a cohort of 61 sporadic colorectal cancer spe-
cimens we found that 4/33 (12.1%) specimens harboring
KRAS mutations were incorrectly classified as KRAS-
WT using regular (conventional) PCR melting curve
analysis and Sanger sequencing, despite dissection of
samples for tumor enrichment. An additional 10/33
KRAS-mutant specimens were close to the limit of
detection using standard melting curve analysis (Table 4
“Lo-Pos”). These findings are supported by recent
reports of false negative or equivocal KRAS results when
less sensitive methods are used [13,17,18]. One study
identified 10/57 (17.5%) additional KRAS-mutant sam-
ples when COLD-PCR was incorporated into high reso-
lution melting curve analysis [17]. Kobunai and
colleagues detected KRAS mutations in an additional 25
out of 224 colorectal tumors when a highly sensitive
PNA-clamping method was compared to direct sequen-
cing [13]. A third group reported equivocal KRAS
results in 10% (18/180) of FFPE tumor specimens using
a melting curve approach that was similar to our assay
without COLD-PCR enhancement [18].
Misclassification of KRAS mutation status has impor-
tant clinical consequences because KRAS testing of
tumor tissue is often used as the sole determinant for
selection of anti-EGFR therapy [19,20]. Taken together,
our data and the results of other recent studies suggest
that more than 10% of patients with KRAS codon 12/13
mutations are incorrectly classified as wild type when
less sensitive methods are used. This has implications
for patient care and for the interpretation of results
from clinical trials that assessed KRAS mutations by
direct sequencing, such as the 2008 landmark New
Regular PCR: Wild Type COLD PCR: G12C
Codon 12 Codon 13
G GG GT C
Codon 12 Codon 13
G G/T G GT C
WT Control
Patient
Temperature ºC
WT Control
Patient
Temperature ºC
-
Δ
F
l
u
o
r
/
 
Δ
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-
Δ
F
l
u
o
r
/
 
Δ
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Re-Classified Specimen
50 58 54 62 66 70 74 50 58 54 62 66 70 74
Figure 5 Re-classified specimen. Shown are results from one of the 4 specimens that was re-classified from KRAS-WT to KRAS-mutant by
COLD-PCR (sample #3 in Additional file 3). With regular PCR no definite mutant allele is detected by the melting curve assay, or by direct
sequencing (left panel). Using COLD-PCR a clear mutant peak is visible in the melting curve assay and confirmed as a G12C mutation by
sequencing (c.34 G > C). Arrows point to the position of the mutant melting peak and mutant base pair position. Note that a Tc of 79.4°C was
used for COLD-PCR sequencing compared to a Tc of 81°C for the COLD-PCR melting curve assay (see Methods), which is the likely explanation
for the higher proportion of mutant allele observed by COLD-PCR sequencing (bottom right).
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colleagues [4].
Previous studies have reported COLD-PCR applied to
KRAS mutational analysis [9,17,21] and COLD-PCR
combined with high-resolution melting curve analysis
[17,22], but to our knowledge this is the first report of
COLD-PCR combined with fluorescent probe-based
melting analysis. Mancini and colleagues applied COLD-
PCR to KRAS mutation detection using the Corbett
Research RotorGene 6000 high resolution melting
instrument [17]. The method described by Zuo et. al.
2009 utilized a ~7 hour full COLD-PCR protocol
followed by a second reaction in a pyrosequencing
instrument and achieved 1.1 to 4.7-fold enhancement
KRAS-mutant signal compared to regular PCR [21]. Mil-
b u r ya n dc o l l e a g u e su s e ds i n g l e - s t e pa n dn e s t e dP C R
conditions followed by high resolution melting curve in
a separate instrument [22]. There are important advan-
tages to the novel strategy we describe here which make
it appealing for the clinical setting compared to earlier
reports. Most importantly, our method is performed as
a single ~1 hour reaction and is entirely closed-tube,
which cuts down substantially on labor and instrument
time, while minimizing the risk of sample handling
errors and contamination. Additionally, compared to
high resolution melting curve analysis, our probe-based
method offers theoretical increased specificity afforded
by 2 primers and 2 probes (compared to 2 primers
only), and better suitability for laboratories that already
own or have experience with the Roche LightCycler®
instrument.
Conclusion
We report a rapid, single-reaction, closed-tube clinical
assay for KRAS mutations that combines COLD-PCR
with melting curve analysis using the LightCycler®
instrument. The assay has a sensitivity of at least 1%,
which is comparable to or better than many commercial
kits and previous studies, although methods with super-
ior sensitivity have been reported [22-24]. In a cohort of
61 colorectal cancer samples, the assay improved diag-
nostic accuracy by correctly identifying 4 KRAS-mutant
samples that were not detected by regular melting curve
analysis or direct sequencing. Incorporation of COLD-
PCR with probe-based melting curve analysis was
straight-forward to optimize and implement, and is
therefore an appealing strategy for assays designed to
detect low-level minority alleles.
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